-
Mashup Score: 0RareCare - National Organization for Rare Disorders - 10 month(s) ago
NORD’s Patient Assistance Programs Since 1987, NORD has provided assistance programs to help patients obtain life-saving or life-sustaining medication they could not otherwise afford. These programs provide medication, financial assistance with insurance premiums and co-pays, diagnostic testing assistance, and travel assistance for clinical trials or consultation with disease specialists. …
Categories: Latest Headlines, Rare DiseaseTweet
-
Mashup Score: 1Emerging Waldenström Macroglobulinemia Treatment Approaches - Patient Empowerment Network - 2 year(s) ago
Dr. Jorge Castillo discusses emerging and promising research and advances in Waldenström macroglobulinemia treatment.
Source: Patient Empowerment NetworkCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 2Clonal hematopoiesis is associated with increased risk of progression of asymptomatic Waldenström macroglobulinemia - PubMed - 2 year(s) ago
Clonal hematopoiesis (CH) is associated with adverse outcomes in patients with non-Hodgkin lymphoma (NHL) and multiple myeloma undergoing autologous stem cell transplantation. Still, its implications for patients with indolent NHL have not been well studied. Here, we report the prevalence of CH in p …
Source: PubMedCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 0Waldenstrom Macroglobulinemia Updates from the IWMF Forum - 2 year(s) ago
A doctor shares important updates from the International Waldenstrom’s Macroglobulinemia Forum (IWMF).
Source: Patient PowerCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Upcoming Program Sessions - IWMF Live Events - 3 year(s) ago
View the latest program sessions on the International Waldenstrom’s Macroglobulinemia Foundation’s Live Events platform.
Source: iwmfevents.comCategories: Latest Headlines, Rare DiseaseTweet
-
Mashup Score: 1Novel agents for Waldenström’s macroglobulinemia - 3 year(s) ago
In this video, Jorge Castillo, MD, of the Dana-Farber Cancer Institute, Boston, MA, discusses the use of novel agents in…
Source: VJHemOncCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 3Cost-effectiveness of zanubrutinib vs rituximab-based therapy in Waldenström’s macroglobulinemia - 3 year(s) ago
Jorge Castillo, MD, Dana-Farber Cancer Institute, Boston, MA, discusses the cost-effectiveness of zanubrutinib versus rituximab-based chemoimmunotherapy in Waldenström’s macroglobulinemia. Dr…
Source: VJHemOncCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 1Mitigation strategies for ibrutinib-associated cardiac AEs in Waldenström’s macroglobulinemia - 3 year(s) ago
Jorge Castillo, MD, Dana-Farber Cancer Institute, Boston, MA, talks on mitigation strategies for ibrutinib-related cardiac toxicity in patients with Waldenström’s…
Source: VJHemOncCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 1Real-world analysis of Waldenström’s macroglobulinemia treatment and resource utilization in the US - 3 year(s) ago
Jorge Castillo, MD, Dana-Farber Cancer Institute, Boston, MA, talks on the real-world treatment patterns, adherence, costs, and healthcare resource utilization…
Source: VJHemOncCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 2Cost-effectiveness of zanubrutinib vs rituximab-based therapy in Waldenström’s macroglobulinemia - 3 year(s) ago
Jorge Castillo, MD, Dana-Farber Cancer Institute, Boston, MA, discusses the cost-effectiveness of zanubrutinib versus rituximab-based chemoimmunotherapy in Waldenström’s macroglobulinemia. Dr…
Source: VJHemOncCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
NORD is proud to offer the @WMIWMF Travel & Lodging Assistance Program! This program helps pay for travel to medical appointments & clinical trials for #WaldenstromsMacroglobulinemia. Apply by phone, email or online here: https://t.co/4c3vNNyMhd #Waldenstroms #Macroglobulinemia https://t.co/70q2JkMpLL